FibroGen Inc. (FGEN)
FibroGen Statistics
Share Statistics
FibroGen has 101.04M shares outstanding. The number of shares has increased by 1.45% in one year.
| Shares Outstanding | 101.04M |
| Shares Change (YoY) | 1.45% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 36.06% |
| Shares Floating | 94.07M |
| Failed to Deliver (FTD) Shares | 15.31K |
| FTD / Avg. Volume | 0.46% |
Short Selling Information
The latest short interest is 4.18M, so 4.14% of the outstanding shares have been sold short.
| Short Interest | 4.18M |
| Short % of Shares Out | 4.14% |
| Short % of Float | 4.87% |
| Short Ratio (days to cover) | 4.75 |
Valuation Ratios
The PE ratio is -0.35 and the forward PE ratio is -0.43. FibroGen's PEG ratio is 0.
| PE Ratio | -0.35 |
| Forward PE | -0.43 |
| PS Ratio | 1.79 |
| Forward PS | 0.1 |
| PB Ratio | -0.29 |
| P/FCF Ratio | -0.38 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for FibroGen.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of -0.4.
| Current Ratio | 1.47 |
| Quick Ratio | 1.45 |
| Debt / Equity | -0.4 |
| Debt / EBITDA | -0.51 |
| Debt / FCF | -0.53 |
| Interest Coverage | -18.24 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $131.65K |
| Profits Per Employee | $-680.44K |
| Employee Count | 225 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 4.93 |
Taxes
| Income Tax | -269K |
| Effective Tax Rate | 0.18% |
Stock Price Statistics
The stock price has increased by -69.91% in the last 52 weeks. The beta is 0.88, so FibroGen's price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | -69.91% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.45 |
| Relative Strength Index (RSI) | 54.97 |
| Average Volume (20 Days) | 3.35M |
Income Statement
In the last 12 months, FibroGen had revenue of 29.62M and earned -153.1M in profits. Earnings per share was -0.48.
| Revenue | 29.62M |
| Gross Profit | 14.06M |
| Operating Income | -150.42M |
| Net Income | -153.1M |
| EBITDA | -142.43M |
| EBIT | -145.12M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
The company has 50.48M in cash and 73.09M in debt, giving a net cash position of -22.61M.
| Cash & Cash Equivalents | 50.48M |
| Total Debt | 73.09M |
| Net Cash | -22.61M |
| Retained Earnings | -1.89B |
| Total Assets | 214.53M |
| Working Capital | 63.2M |
Cash Flow
In the last 12 months, operating cash flow was -138M and capital expenditures -266K, giving a free cash flow of -138.26M.
| Operating Cash Flow | -138M |
| Capital Expenditures | -266K |
| Free Cash Flow | -138.26M |
| FCF Per Share | -1.38 |
Margins
Gross margin is 47.47%, with operating and profit margins of -507.8% and -516.86%.
| Gross Margin | 47.47% |
| Operating Margin | -507.8% |
| Pretax Margin | -517.76% |
| Profit Margin | -516.86% |
| EBITDA Margin | -480.83% |
| EBIT Margin | -507.8% |
| FCF Margin | -466.78% |
Dividends & Yields
FGEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FGEN is $10, which is 2841.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 2841.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -14.07 |
| Piotroski F-Score | 2 |